3 results
Primary1. To demonstrate that 89Zr-CER-001 penetrates into atherosclerotic plaques in patients by means of PET imaging. Secondary 2. To evaluate whether the amount of 89Zr-CER-001 penetrating the plaque corresponds to athero-lesion severity.3. To…
Primary:To determine the safety, tolerability, and pharmacokinetic (PK) profile of single ascending intravenous (iv) doses and of multiple ascending iv doses of FMX-8 in healthy subjectsSecondary:To evaluate the pharmacodynamics (PD) of FMX-8 in…
Therapy:The investigational product, ACP-196, will be supplied as hardgelatin capsules for oral administration.Commercially available ibrutinib (IMBRUVICA®) will be used asthe reference therapy.Objectives: Primary Objective:To assess whether ACP-196…